guest ::
| Home > Publications database > CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. > print |
| Home > Publications database > CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. > print |
| 001 | 304580 | ||
| 005 | 20250916115009.0 | ||
| 024 | 7 | _ | |a 10.3390/ijms26178235 |2 doi |
| 024 | 7 | _ | |a pmid:40943160 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC12428420 |2 pmc |
| 024 | 7 | _ | |a 1422-0067 |2 ISSN |
| 024 | 7 | _ | |a 1661-6596 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2025-01903 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 540 |
| 100 | 1 | _ | |a Givi, Sedigheh |b 0 |
| 245 | _ | _ | |a CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. |
| 260 | _ | _ | |a Basel |c 2025 |b Molecular Diversity Preservation International |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1757942235_16315 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Chimeric antigen receptor (CAR) T-cell therapy directed to CD19 and B-cell maturation antigen has revolutionized treatment of B-cell leukemia and lymphoma, and multiple myeloma. However, identifying suitable targets for acute myeloid leukemia (AML) remains challenging due to concurrent expression of potential target antigens on normal hematopoietic stem cells or tissues. As the stress-induced B7H6 molecule is rarely found on normal tissues but expressed on many cancers including AML and melanoma, the NKp30-ligand B7H6 emerges as a promising target for NKp30-based CAR T therapy for these tumors. In this study, we report a comprehensive B7H6 expression analysis on primary AML and melanoma as well as on different tumor cell-lines examined by RT-qPCR and flow cytometry, and efficient anti-tumor reactivity of NKp30-CAR T cells to AML and melanoma. To overcome limitations of autologous CAR T-cell fitness-dependent efficacy and patient-tailored production, we generated CRISPR/Cas9-mediated TCR-knockout (TCRKO) NKp30-CAR T cells as an off-the-shelf approach for CAR T therapy. Functional studies comparing NKp30-CD28 CAR or NKp30-CD137 CAR TCR+ and TCRKO T lymphocytes revealed superior anti-tumoral immunity of NKp30-CD28 CAR TCRKO T cells to AML and melanoma cell lines in vitro, and effective control of tumor burden in an NSG melanoma-xenograft mouse model. In conclusion, these findings highlight the therapeutic potential of NKp30 CAR TCRKO T cells for adoptive T-cell therapy to B7H6-expressing cancers, including melanoma and AML. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a B7H6 expressing tumors |2 Other |
| 650 | _ | 7 | |a CAR T-cell therapy |2 Other |
| 650 | _ | 7 | |a NKp30-based CAR T-cell therapy |2 Other |
| 650 | _ | 7 | |a acute myeloid leukemia |2 Other |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 650 | _ | 7 | |a melanoma |2 Other |
| 700 | 1 | _ | |a Lohnes, Benedikt J |0 0009-0006-3362-6546 |b 1 |
| 700 | 1 | _ | |a Ebrahimi, Saber |b 2 |
| 700 | 1 | _ | |a Riedel, Sophie |b 3 |
| 700 | 1 | _ | |a Khokhali, Sneha |b 4 |
| 700 | 1 | _ | |a Khan, Shamsul A |b 5 |
| 700 | 1 | _ | |a Keller, Maximilian |0 0009-0001-9092-6290 |b 6 |
| 700 | 1 | _ | |a Wölfel, Catherine |b 7 |
| 700 | 1 | _ | |a Echchannaoui, Hakim |0 P:(DE-He78)d32743f5aa1b7577cded5ce1d6c153bf |b 8 |
| 700 | 1 | _ | |a Bockamp, Ernesto |b 9 |
| 700 | 1 | _ | |a Andre, Maya C |b 10 |
| 700 | 1 | _ | |a Abken, Hinrich |0 0000-0002-4302-3240 |b 11 |
| 700 | 1 | _ | |a Theobald, Matthias |0 0000-0002-4270-2209 |b 12 |
| 700 | 1 | _ | |a Hartwig, Udo F |0 0000-0002-6714-6923 |b 13 |
| 773 | _ | _ | |a 10.3390/ijms26178235 |g Vol. 26, no. 17, p. 8235 - |0 PERI:(DE-600)2019364-6 |n 17 |p 8235 |t International journal of molecular sciences |v 26 |y 2025 |x 1422-0067 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:304580 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)d32743f5aa1b7577cded5ce1d6c153bf |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 0000-0002-4270-2209 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 0000-0002-6714-6923 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-21 |
| 920 | 1 | _ | |0 I:(DE-He78)FM01-20160331 |k FM01 |l DKTK Koordinierungsstelle Frankfurt |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)FM01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|